ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Immunotherapies Show Promise in Small-Cell Lung Cancer

Immunotherapies Show Promise in Small-Cell Lung Cancer

 

Immunotherapy has shown efficacy in lung cancer, with several drugs already approved for patients with non–small-cell lung cancer (anti–PD-1 agent nivolumab, anti–PD-L1 agents pembrolizumab and atezolizumab)‎.

In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses immunotherapies in the small-cell lung cancer (SCLC) setting.

Kalemkerian reviews the results of several trials in SCLC, including nivolumab monotherapy or in combination with the CTLA-4 blocker ipilimumab, and pembrolizumab.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.